223P Efficacy and safety of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) in Chinese patients (Pts) with metastatic adenocarcinoma of the pancreas (MPC): A phase II study

Xianjun Yu(Fudan University Shanghai Cancer Center), Rui Xu(Sun Yat-sen University), Jin Hao(Zhejiang University Medical College Affiliated Stomatological Hospital), Hongming Pan(Sir Run Run Shaw Hospital), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Guohong Han(Medical Center Hospital), L. Wang(Shanghai Second People's Hospital), Lin Shen(Peking University), Damir Begic, Jianming Xu(Chinese PLA General Hospital), Y. Zhang(Harbin Institute of Technology), Bing Lu(Academy of Military Medical Sciences), S. Yang(Zhengzhou University), Muye Li(Kunming Medical University)
Annals of Oncology
December 1, 2015
10.1093/annonc/mdv523.84
Cited by 0

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775